BRWA
AUPH icon

B. Riley Wealth Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

B. Riley Wealth Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,860
Closed -$97.5K – 1330
2024
Q4 		$97.5K Sell
10,860
-552
-5% -$4.5K ﹤0.01% 1104
2024
Q3 		$82.3K Sell
11,412
-3,334
-23% -$20.7K ﹤0.01% 1221
2024
Q2 		$84.2K Buy
+14,746
New +$77.7K ﹤0.01% 1319

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

B. Riley Wealth Advisors's AUPH Position: Q1 2025 in Review

B. Riley Wealth Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2025, closing a stake of 10,860 shares — an estimated $97.5K sold.

B. Riley Wealth Advisors first reported a position in AUPH in Q2 2024 and held it in 3 quarters. The position peaked at $97.5K in Q4 2024. 214 funds tracked by Wall St. Rank hold AUPH as of Q1 2025.

  • B. Riley Wealth Advisors reported no remaining Aurinia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 10,860 Aurinia Pharmaceuticals shares in Q1 2025, an estimated $97.5K.
  • B. Riley Wealth Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • B. Riley Wealth Advisors's Aurinia Pharmaceuticals position peaked at $97.5K in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2025.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2025, filed 28 Aug 2026.